期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DPP-4抑制剂对糖尿病肾病的保护作用 被引量：3

Protective effect of DPP-4 inhibitors on diabetic nephropathy
原文传递
导出
摘要 高血糖是糖尿病肾病发病的重要原因之一.二肽基肽酶-4（DPP-4）抑制剂可减少胰高血糖素样肽-1（GLP-1）降解,改善机体高血糖状态,从而延缓糖尿病肾病病程的进展.此外,DPP-4抑制剂还可影响其他与糖尿病肾病相关的非GLP-1底物,如基质细胞衍生因子-1α、脑钠尿肽及金属内肽酶的表达,继而发挥GLP-1非依赖性的肾脏保护作用.研究DPP-4抑制剂对糖尿病患者肾脏的保护作用及其机制,将为其在糖尿病肾病治疗中的应用提供新的认识. Hyperglycemia is the most important risk factors of diabetic nephropathy.Dipeptidyl peptidase-Ⅳ （DPP-4） inhibitors can improve hyperglycemia via reduction of glucagon-like peptide-1 （GLP-1）degradation,thereby protecting against the development and progression of diabetic nephropathy.Furthermore,DPP-4 inhibitors have renal protective effect independent of GLP-1 through influencing the expression of other DPP-4 substrates,for example,stromal cell-derived factor-1α,brain natriuretic peptide and metal endopeptidase,which are related to the progression of diabetic nephropathy.Further study of renal protective effect of DPP-4 inhibitors in diabetic patients and the relevant mechanism,may provide new insights of the treatment in diabetic nephropathy with DPP-4 inhibitors.
作者 许文伟 关美萍 薛耀明
机构地区 南方医科大学南方医院内分泌代谢科
出处 《国际内分泌代谢杂志》 北大核心 2013年第6期383-385,共3页 International Journal of Endocrinology and Metabolism
关键词 二肽基肽酶-Ⅳ 二肽基肽酶-Ⅳ抑制剂 糖尿病肾病 Dipeptidyl peptidase-Ⅳ Dipeptidyl peptidase-Ⅳ inhibitors Diabetic nephropathy
分类号 R587.2 [医药卫生—内分泌] R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献18

  • 1Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase 1V in-hibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther,2012,340:248-255.
  • 2Lone AM, Nohe WM, Tinoco AD, et al. Peptidomics of the prolyl peptidases. AAPS J,2010,12:483-491.
  • 3Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (Lond),2013,124:17-26.
  • 4Namba M, Katsuno T, Kusunoki Y, et al. New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Clin Exp Nephrol,2013,17:10-15.
  • 5Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res, 2011,2011:162092.
  • 6王晓兢,武晓泓.营养物质刺激肠道L细胞分泌GLP-1的机制[J].国际内分泌代谢杂志,2011,31(5):324-326. 被引量：4
  • 7Thomson SC, Kashkouli A, Singh P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol,2013,304: F137-F144.
  • 8Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like pep- tide-1 receptor agonist ameliorates renal injury through its an- ti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia,2011,54:965-978.
  • 9Ishibashi Y, Nishino Y, Matsui T, et al. Glucagon-like peptide- 1 sup- presses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism,2011,60:1271-1277.
  • 10Hirata K, Kume S, Araki S, et al. Exendin-4 has an anti-hy- pertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun,2009,380:44-49.

二级参考文献49

  • 1王燕萍,刘礼斌.GLP-1对胰岛β细胞保护作用的研究进展[J].国际内分泌代谢杂志,2007,27(2):98-100. 被引量：7
  • 2D'Alessio D,Lu W,Sun W,et al.Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma:evidence for selective release of GLP-1 in the lymph system.Am J Physiol integr Cutup physiol,2007,293:2163-2169.
  • 3Deacon CF.What do we know about the secretion and degradation of incretin hormones? Regul Pept,2005,128:117-124.
  • 4De Leon DD,Crutchlow MF,Ham JY,et al.Role of glucagonslike peptide-1 in the pathogenesis and treatment of diabetes mellitus.Int J Biochem Cell Biol,2006,38:845-859.
  • 5Nagell CF,Wettergren A,Orskov C,et al.Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs.Scand J Gastroenterol,2006,41:667-672.
  • 6Nakade Y,Tsukamoto K,Pappas 'IN,et al.Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheralsympathetic pathway in rats.Brain Res,2006,1111:117-121.
  • 7Pannacciulli N,Le DS,Salbe AD,et al.Postprandial glucagon-like peptide (GLP-1)response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans.Neuroimage,2007,35:511-517.
  • 8Osaka T,Endo M,Yamakawa M,et al.Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system.Peptides,2005,26:1623-1631.
  • 9Fehse F,Trautmann M,Hoist J J,et al.Exenatide augments firstand second-phase insulin secretion in response to intravenous glucase in subjects with type 2 diabetes.J Clin Endocrinol Metab,2005,90:5991-5997.
  • 10Penfornis A,Borot S,Raccah D.Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.Diabetes Metab,2008,34(Suppl 2):S78-S90.

共引文献9

同被引文献60

  • 1Ahren B.Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes[J].Emerging Drugs,2008,13(1):593-607.
  • 2Dhillon S.Sitagliptin:a review of its use in the management of type 2diabetes mellitus[J].Drugs,2010,70(4):489-512.
  • 3Liu W J,Xie S H,Liu Y N,et al.Dipeptidyl peptidase IV in-hibitor attenuates kidney injury in strepozotocin-induced diabetic rats[J].J Pharmacol Exp Ther,2012,340(2):248-255.
  • 4Glorie L L,Verhulst A,Marheeussen V,et al.DPP-4 inhibition improves functional outcome after renal ischemia-reperfusion injury[J].Am J Physiol Renal Physiol,2012,303(5):F681-688.
  • 5Alter M L,Ott I M,von Websky K,et al.DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy[J].Kidney&Blood Pressure Research,2012,36(1):119-130.
  • 6Panchapakesan U,Mather A,Pollock C.Role of GLP-1 and DPP-4in diabetic nephropathy and cardiovascular disease[J].Clin Sci(Lond),2013,124(6):17-26.
  • 7Tran S,Dahlback B.Novel APC-cleavge sites in FV a provide insights into mechanisms of action of APC and its cofactor protein S[J].J Thromb Haemost,2010,8(1):129-136.
  • 8Brosius F C,Khoury C C,Buller C L,et al.Abnormalities in signaling pathways in diabetic nephropathy[J].Expert Rev Endocrinol Metab,2010,5(1):51-64.
  • 9Isermann B,Vinnikov I A,Madhusudhan T,et al.Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis[J].Nat Med,2007,13(11):1349-1358.
  • 10Brosius F C,Khoury C C,Buller C L,et al.Abnormalities in signaling pathways in diabetic nephropathy[J].Expert Rev Endocrinol Metab,2010,5(1):51-64.

引证文献3

二级引证文献17

国际内分泌代谢杂志
2013年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部